TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03104504

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Suicide Risk Screening
Description: Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safety Planning
Description: Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Care transition facilitation
Description: Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A Lean Implementation Strategy
Description: The Interventions will be implemented using Lean performance improvement strategies
Study: NCT03864367

Intervention type: DEVICE
Intervention: Device - Prism Medical FGA-700 Bariatric Floor Lift
Description: This group will be using a Mobile Weight-Support Therapy (MWeST) device (the Prism Medical FGA-700 Bariatric Floor Lift) to determine if it improves mobilization of older patients with traumas of their legs.
Study: NCT01299272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2216684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.
Study: NCT03303807

Intervention type: DEVICE
Group type: OTHER
Intervention: Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)
Description: A low-flow CO2 removal device (Prismalung®, Baxter) will be used with a conventional renal replacement therapy (RRT) platform (Prismaflex®, Baxter). In patients already treated with continuous RRT because of renal failure or metabolic acidosis, the HF 1400® (Baxter) set will be used to combine RRT and decarboxylation. Gas flow through the gas exchanger will be set up to 10 L/min, with an oxygen concentration from 0.21 to 1 and a blood flow of 200-400 mL/min. Patients will be ventilated with a target tidal volume of 6 ml/kg (predicted body weight) and a target plateau pressure below 30 cmH2O.
Study: NCT00442338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 14 mg single injection (IV bolus administration) over 5 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aminophylline hydrate
Description: Aminophylline 250 mg IV drip infusion over 60 minutes
Study: NCT02703974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early handwashing station
Description: A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete.
Study: NCT02113020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-233
Description: Oral administration of TAK-233

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral admininstration of Placebo
Study: NCT02211833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Study: NCT02703974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early handwashing station
Description: A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Late handwashing station
Description: A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3.
Study: NCT02211833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study: NCT03143244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine group (D)
Description: Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
Study: NCT02703974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late handwashing station
Description: A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3.
Study: NCT03143244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac-Midazolam group (KM)
Description: Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Normal Saline) (C)
Description: Patients received normal saline in two sets
Study: NCT02703974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: A nudge will be built in each randomly selected school and will consist of:~1. Connecting latrines to the handwashing station via paved pathways that are painted bright colors~2. Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations~The nudges will be constructed at the end of week 3 and 4, after Phase II data collection is complete within each randomly assigned nudge school.
Study: NCT01340339

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
Study: NCT03144076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RSBY Health Insurance
Description: RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
Study: NCT03231371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
Study: NCT00638547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRT Laronidase
Description: Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture
Study: NCT01959581

Intervention type: DEVICE
Group type: OTHER
Intervention: Movement Enhancing Device
Description: Naturalistic play activities using the hands while wearing the movement enhancing device.
Study: NCT03639155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat reference tablets
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat test tablets
Description: oral tablet
Study: NCT01061294

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Advanced CustomVue™ iLASIK procedure

Intervention type: DEVICE
Group type: OTHER
Intervention: WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System
Study: NCT02535195

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginger supplement
Study: NCT02535195

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (starch)
Study: NCT01675180

Intervention type: OTHER
Group type: OTHER
Intervention: Information
Description: Women in the intervention group will recieve information and counseling on oral health care during pregnancy

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention
Study: NCT06271096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra muscular Midazolam
Description: ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
Study: NCT02703974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:~* Importance of handwashing~* Method of handwashing~* Critical times of handwashing~* Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.~The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:~* Importance of handwashing~* Method of handwashing~* Critical times of handwashing~* Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.~The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school.
Study: NCT03144076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RSBY Health Insurance
Description: RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RSBY Health Insurance
Description: RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
Study: NCT03907540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg tablet
Description: Belumosudil 200 mg tablet, development candidate
Study: NCT06271096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravascular Diazepam
Description: ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
Study: NCT04983147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obesity Training Based on Health Belief Model
Description: Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obesity Training Based on Health Belief Model
Description: Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obesity Training Based on Health Belief Model
Description: Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obesity Training Based on Health Belief Model
Description: Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.
Study: NCT03495557

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Fascial closure with simple polydioxanone suture 2/0 stitches

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Onlay polypropylene mesh placement (MN mesh)
Study: NCT02570789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patients with sunitinib or pazopanib
Description: The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
Study: NCT02092870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived stem cells
Description: ASCs harvested from autologous lipoaspirate
Study: NCT03907540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose
Description: test investigational medicinal product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-KD025 200 mg capsule
Description: test investigational medicinal product
Study: NCT03480555

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Replenish Protein
Description: Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard protein
Description: Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
Study: NCT00345579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014
Description: 3-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB
Description: 3-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix/Infanrix Penta
Description: 3-dose intramuscular injection
Study: NCT02183701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan + Hydrochlorothiazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00345579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix/Infanrix Penta
Description: 3-dose intramuscular injection
Study: NCT01002599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boussignac TM CPAP
Description: Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi Face Mask
Description: Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
Study: NCT03323099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: N-of-1
Description: Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Data Tracking
Description: Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
Study: NCT05247944

Intervention type: PROCEDURE
Intervention: Fenestrated and branched endovascular aortic repair (F-BEVAR)
Description: Fenestrated and branched endovascular aortic repair (F-BEVAR)

Intervention type: PROCEDURE
Intervention: Open repair
Description: Open surgery for complex abdominal aortic aneurysm
Study: NCT00541762

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fat perfusion to the small intestine
Description: 1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~2. Orlistat perfused to the small intestine~3. DEXLOX as CCK-1 receptor antagonist
Study: NCT01170897

Intervention type: DRUG
Group type: OTHER
Intervention: PEGPH20
Description: PEGylated Recombinant Human Hyaluronidase
Study: NCT03746080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy (WBRT)
Description: Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiotherapy consists of 30 Gy in 15 fractions
Study: NCT04174677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Infusion of Inebilizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Infusion of VIB4920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilzumab+VIB4920
Description: Infusion of Inebilizumab and VIB4920
Study: NCT01030224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9742
Description: Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZD9742
Description: Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
Study: NCT01961830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1100 inhalation solution
Study: NCT03833544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Progressive resistance training of hip, knee, and ankle flexors.
Study: NCT01813526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Nutritionally complete free amino acid-based medical food.
Study: NCT00720616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin
Description: Norditropin 0.1 mg/day self-administered once a day subcutaneously
Study: NCT01955876

Intervention type: DRUG
Intervention: Lanthanum Carbonate (Fosrenol, BAY77-1931)
Description: Patients treated with Fosrenol in daily clinical practice.
Study: NCT00286143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
Study: NCT03029208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
Study: NCT05500456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear aligners
Description: Each aligner will be worn for about two weeks, and then replaced by the next in the series until the final position is achieved.
Study: NCT03029208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron therapy
Description: Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron therapy
Description: Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
Study: NCT00951067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise, Elevation, and Compression Garment
Description: Patients will be asked to daily:~* exercise~* elevate arm~* wear an arm compression garment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E0650 PCD with non-sequential waveform
Description: Use of an E0650 PCD with non-sequential waveform for two hours every day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E0651 PCD with sequential, non-gradient waveform
Description: Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
Study: NCT05500456

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed appliances
Description: Conventional wires and brackets will be used.
Study: NCT00951067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E0652 PCD with sequential, gradient waveform
Description: Use of an E0652 PCD with sequential, gradient waveform for two hours every day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E0652 PCD with peristaltic pulse waveform
Description: Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
Study: NCT02591173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.